Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00744055 · ClinicalTrials.gov registry record · Phase 3
Prazosin for Treatment of Patients With Alcohol Dependence (AD) and Post Traumatic Stress Disorder (PTSD).
A Phase 3 study of Stress Disorders, Post-Traumatic and Alcohol Dependence, sponsored by Yale University.
- Completed
- Registry status
- Phase 3
- Development phase
- 96
- Enrollment target
- 1
- Study location
NCT00744055: Completed Phase 3 study of Stress Disorders, Post-Traumatic and Alcohol Dependence, sponsored by Yale University.
NCT00744055 is a Phase 3 study of Stress Disorders, Post-Traumatic and Alcohol Dependence that has completed, run by Yale University. The registered enrollment target is 96 participants, below the 155-participant average among 66 other Stress Disorders, Post-Traumatic trials with a reported enrollment target (38% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00744055, a Phase 3 study of Stress Disorders, Post-Traumatic and Alcohol Dependence, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 96 participants
- Enrollment target
- 1
- Study location
Study Summary
Prazosin is an alpha-1 adrenergic receptor antagonist that has been used successfully in the treatment of trauma nightmares and sleep disturbance in combat veterans with PTSD, and alcohol dependence. The objective of this study is to evaluate the efficacy of prazosin (16mg) versus placebo in reducing alcohol consumption and decreasing symptoms of PTSD in patients with comorbid AD and PTSD.
Primary Outcome
Using the Timeline Follow Back method, a calendar method for assessing drug and alcohol use
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Prazosin
Study Locations (1)
Connecticut
- VA Connecticut Healthcare System - West Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2009-01 |
| Est. Completion | 2014-10 |
| Phase | Phase 3 |
What the finished NCT00744055 record still lists
NCT00744055 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 96 participants, a relatively small participant target, below the 155-participant average among 66 other Stress Disorders, Post-Traumatic trials with a reported enrollment target (38% lower).
The record links to 2 conditions, with Stress Disorders, Post-Traumatic appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00744055 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT00744055 about?
NCT00744055 is a clinical study titled "Prazosin for Treatment of Patients With Alcohol Dependence (AD) and Post Traumatic Stress Disorder (PTSD).". Prazosin is an alpha-1 adrenergic receptor antagonist that has been used successfully in the treatment of trauma nightmares and sleep disturbance in combat veterans with PTSD, and alcohol dependence. The objective of this study is to evaluate the efficacy of prazosin (16mg) versus placebo in reduci...
What is the current status of trial NCT00744055?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 96 participants. The study started on 2009-01. Estimated completion is 2014-10.
What conditions does trial NCT00744055 study?
This clinical trial studies the following conditions: Stress Disorders, Post-Traumatic, Alcohol Dependence.
What interventions are being tested in trial NCT00744055?
The interventions under investigation include: Placebo (DRUG), Prazosin (DRUG).
Who is sponsoring clinical trial NCT00744055?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00744055 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stress Disorders, Post-Traumatic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00744055's enrollment target sits among peer trials
96 31st of 66 higher than 36 of 66 other Stress Disorders, Post-Traumatic trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stress Disorders, Post-Traumatic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Fluoxetine vs EMDR to Treat Post-Traumatic Stress Disorder (PTSD)
COMPLETED · Phase 3
-
Cognitive Behavioral Therapy (CBT) for Posttraumatic Stress Disorder (PTSD) in Community Addiction Treatment
COMPLETED · Phase 3
-
Manage Emotions to Reduce Aggression (MERA)
RECRUITING · NA
-
SMART Therapist Training: A Hybrid Factorial-SMART Design
RECRUITING · NA
-
Overcontrol and Suicide in PTSD
RECRUITING
-
Postpartum Care in the NICU (PeliCaN) Transitions
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03401762 · 96 participants · NA
Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke
- NCT03471260 · 96 participants · Phase 1
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- NCT03549559 · 96 participants · NA
Imaging Histone Deacetylase in the Heart
- NCT03841058 · 96 participants · Phase 2
Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia